Debt-to-equity in % of Kalaris Therapeutics, Inc. from Q1 2021 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kalaris Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q1 2021 to Q3 2025.
  • Kalaris Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 281 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Kalaris Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 281 +316 Sep 30, 2025
Q2 2025 -199 -457 -177% Jun 30, 2025
Q1 2025 -62.3 -115 -218% Mar 31, 2025
Q4 2024 -32.5 -67.8 -192% Dec 31, 2024
Q3 2024 -34.6 -59.5 -239% Sep 30, 2024
Q2 2024 258 +236 +1080% Jun 30, 2024
Q1 2024 52.8 +30.5 +136% Mar 31, 2024
Q4 2023 35.3 +14.2 +67.5% Dec 31, 2023
Q3 2023 24.9 +2.78 +12.6% Sep 30, 2023
Q2 2023 21.9 -0.88 -3.86% Jun 30, 2023
Q1 2023 22.4 +4.62 +26% Mar 31, 2023
Q4 2022 21.1 +7.16 +51.5% Dec 31, 2022
Q3 2022 22.1 +13.1 +145% Sep 30, 2022
Q2 2022 22.8 +16.6 +271% Jun 30, 2022
Q1 2022 17.7 +10.2 +135% Mar 31, 2022
Q4 2021 13.9 Dec 31, 2021
Q3 2021 9.01 Sep 30, 2021
Q2 2021 6.14 Jun 30, 2021
Q1 2021 7.55 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.